Lates News

Theravance Biopharma (TBPH.US) financial report for Q1 2025 shows revenue of $15.388 million, compared to the previous value of $14.503 million and an expected value of $28.07 million; earnings per share were -$0.27, compared to the previous value of -$0.09 and an expected value of -$0.09.